Medical device firm Capitan Orthopedics closed an oversubscribed seed round, bringing its total capital raised to date to $4.1 million.
The company intends to use the funds to continue project development and validation efforts and begin its first in-human clinical trial, which is expected to start in the first quarter of 2027, according to an Aug. 18 news release.
The seed round was oversubscribed by over $1.1 million dollars.
The company’s SupraSpacer is intended for patients with an irreparable rotator cuff tear. The metallic implant preserves 90% of the humeral head cartilage and uses a seven-step surgical procedure.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
